Differential methylation and expression of genes in the hypoxia-inducible factor 1 signaling pathway are associated with paclitaxel-induced peripheral neuropathy in breast cancer survivors and with preclinical models of chemotherapy-induced neuropathic pain.

Kord M. Kober,Man-Cheung Lee,Adam B. Olshen,Yvette P. Conley,Marina Sirota,Michael J. Keiser,Marilyn J. Hammer,Gary Abrams,Mark Schumacher,Jon D. Levine,Christine Miaskowski

Differential methylation and expression of genes in the hypoxia-inducible factor 1 signaling pathway are associated with paclitaxel-induced peripheral neuropathy in breast cancer survivors and with preclinical models of chemotherapy-induced neuropathic pain.

2020

Kord M. Kober
Man-Cheung Lee
Adam B. Olshen
Yvette P. Conley
Marina Sirota
Michael J. Keiser
Marilyn J. Hammer
Gary Abrams
Mark Schumacher
Jon D. Levine
Christine Miaskowski

BackgroundPaclitaxel is an important chemotherapeutic agent for the treatment of breast cancer. Paclitaxel-induced peripheral neuropathy (PIPN) is a major dose-limiting toxicity that can persist in...

Keywords:

Breast cancer
Anesthesia
Paclitaxel
Cancer research
Hypoxia-inducible factors
Neuropathic pain
Medicine
Peripheral neuropathy
Chemotherapy
Signal transduction
Toxicity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

136

References

Citations